# The BODE (Body Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity) Index in Chronic Obstructive Pulmonary Disease: A Comprehensive Clinical Assessment Tool

## TL;DR

The BODE index improves COPD assessment by combining body mass, lung function, breathlessness, and exercise ability, offering better predictions than traditional methods.

## Contribution

The BODE index is shown to outperform FEV₁ and GOLD staging in predicting COPD outcomes, with modified versions enhancing its clinical applicability.

## Key findings

- The BODE index outperforms FEV₁ and GOLD staging in predicting mortality, exacerbations, and hospitalizations in COPD.
- Modified versions like ADO and i-BODE improve feasibility in primary care and rehabilitation settings.
- The index captures both pulmonary and systemic disease burden, supporting better risk stratification.

## Abstract

Chronic obstructive pulmonary disease (COPD) is a heterogeneous condition with systemic effects extending beyond airflow limitation. Spirometry alone is insufficient for a comprehensive assessment. The BODE index, which integrates body mass index, airflow obstruction, dyspnea, and exercise capacity, was developed to improve prognostication by capturing multiple dimensions of disease burden.

This systematic review, conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines, searched PubMed, Embase, Scopus, and the Cochrane Library up to August 2025. Eligibility was defined using the PICO framework, and risk of bias was assessed with the Newcastle-Ottawa Scale and QUIPS tool.

From 128 records, five studies comprising 2,482 patients with COPD were included. The BODE index consistently outperformed FEV₁ and GOLD staging in predicting mortality, exacerbations, and hospitalizations. Modified indices, such as the ADO (age, dyspnea, obstruction) and i-BODE (incremental shuttle walk test in place of six-minute walk distance), enhanced feasibility and calibration in primary care and rehabilitation settings. Across studies, outcome ascertainment was robust, with an overall low to moderate risk of bias.

The BODE index provides a multidimensional and clinically meaningful approach to COPD evaluation, surpassing spirometry by reflecting both pulmonary and systemic disease burden. It supports better risk stratification for clinical management and research. Future studies should explore integration with biomarkers, imaging, and digital tools to refine prognostic accuracy and guide personalized care.